<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01821781</url>
  </required_header>
  <id_info>
    <org_study_id>201301135</org_study_id>
    <nct_id>NCT01821781</nct_id>
  </id_info>
  <brief_title>Immune Disorder HSCT Protocol</brief_title>
  <official_title>A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Immune Function Disorders Using a Reduced Intensity Preparatory Regime</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study hypothesizes that a reduced intensity immunosuppressive preparative regimen will
      establish engraftment of donor hematopoietic cells with acceptable early and delayed toxicity
      in patients with immune function disorders. A regimen that maximizes host immune suppression
      is expected to reduce graft rejection and optimize donor cell engraftment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with donor engraftment</measure>
    <time_frame>1 year post transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Transplant Related Toxicities</measure>
    <time_frame>1 years post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to neutrophil recovery</measure>
    <time_frame>within 100 days post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patient with acute GVHD</measure>
    <time_frame>180 days post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with infectious complications</measure>
    <time_frame>2 years post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to immune reconstitution</measure>
    <time_frame>2 years post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to platelet recovery</measure>
    <time_frame>within 100 days post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with chronic GVHD</measure>
    <time_frame>2 years post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>2 years post transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Immune Deficiency Disorders</condition>
  <condition>Severe Combined Immunodeficiency</condition>
  <condition>Chronic Granulomatous Disease</condition>
  <condition>X-linked Agammaglobulinemia</condition>
  <condition>Wiskott-Aldrich Syndrome</condition>
  <condition>Hyper-IgM</condition>
  <condition>DiGeorge Syndrome</condition>
  <condition>Chediak-Higashi Syndrome</condition>
  <condition>Common Variable Immune Deficiency</condition>
  <condition>Immune Dysregulatory Disorders</condition>
  <condition>Hemophagocytic Lymphohistiocytosis</condition>
  <condition>IPEX</condition>
  <condition>Autoimmune Lymphoproliferative Syndrome</condition>
  <condition>X-linked Lymphoproliferative Syndrome</condition>
  <arm_group>
    <arm_group_label>Preparative</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan</intervention_name>
    <description>Between days -23 and -15: alemtuzumab test dose, 3mg IV or SQ Day -14: alemtuzumab, 10mg IV or SQ Day -13: alemtuzumab, 15mg IV or SQ Day -12: alemtuzumab, 20mg IV or SQ Days -8 to -4: fludarabine, 30mg/m2 IV Day -4: thiotepa 4mg/kg IV q 12 hours Day -3: melphalan, 140mg/m2 IV Day 0: stem cell infusion Day +7: G-CSF</description>
    <arm_group_label>Preparative</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &lt;/= 21 years of age

          -  Performance status &gt;/= 40

          -  DLCO &gt;/= 40%

          -  LVEF &gt;/=40% or LVSF &gt;/=26%

          -  Serum creatinine &lt; 2x ULN

          -  Liver enzymes &lt;/= 5x ULN

          -  Negative pregnancy test

          -  Suitably matched donor (6/6 matched sib UCB, 8/8 matched sib BM or PBSC, 5-6/6 matched
             unrelated UCB, 7-8/8 matched unrelated BM, double cord)

        Exclusion Criteria:

          -  Known diagnosis of HIV I/II

          -  Pregnant or breastfeeding

          -  Uncontrolled invasive fungal or bacterial infections within 1 month prior to starting
             alemtuzumab

          -  Uncontrolled viral infection within 1 week prior to starting alemtuzumab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Bednarski, MD</last_name>
      <phone>314-454-6018</phone>
      <email>Bednarski_J@kids.wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Murray, CCRP</last_name>
      <phone>314-454-4240</phone>
      <email>Murray_L@kids.wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jeffrey Bednarski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Heathcare</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Troy Quigg, DO, MS</last_name>
      <email>Troy.Quigg@mhshealth.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2013</study_first_submitted>
  <study_first_submitted_qc>March 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2013</study_first_posted>
  <last_update_submitted>November 17, 2017</last_update_submitted>
  <last_update_submitted_qc>November 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immune deficiency</keyword>
  <keyword>Immune disorders</keyword>
  <keyword>Immune dysregulatory</keyword>
  <keyword>Reduced Intensity</keyword>
  <keyword>Alemtuzumab</keyword>
  <keyword>Campath</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Granulomatous Disease, Chronic</mesh_term>
    <mesh_term>Severe Combined Immunodeficiency</mesh_term>
    <mesh_term>Lymphohistiocytosis, Hemophagocytic</mesh_term>
    <mesh_term>Wiskott-Aldrich Syndrome</mesh_term>
    <mesh_term>DiGeorge Syndrome</mesh_term>
    <mesh_term>Agammaglobulinemia</mesh_term>
    <mesh_term>Autoimmune Lymphoproliferative Syndrome</mesh_term>
    <mesh_term>Chediak-Higashi Syndrome</mesh_term>
    <mesh_term>Genetic Diseases, X-Linked</mesh_term>
    <mesh_term>Common Variable Immunodeficiency</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

